• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    O

    Ospedale San Filippo Neri

    EST. 1940
    190论文总数
    5,063引用总数

    论文量&引用量时间轴

    机构学者

    论文(190)

    年份
    起
    –
    止
    排序
    1Are SGLT2 Inhibitors Really Associated with Increased Urinary Tract Infection Risk? A Trial-Level Meta-Analysis Across Type 2 Diabetes, Heart Failure, and Chronic Kidney Disease
    Andrea Matteucci,Stefania Angela Di Fusco,Michela Bonanni,Lorenzo Castello, Stefano Aquilani,Silvio Fedele,Federico Nardi,Furio Colivicchi

    Sodium-glucose cotransporter 2 (SGLT2) inhibitors are established therapies across the cardiovascular–renal continuum. Although the excess risk of external genital infection is well recognized, the association between SGLT2 inhibition and urinary tract infection (UTI), particularly serious/complicated urinary infection, remains uncertain. We conducted a systematic review and meta-analysis of randomized placebo-controlled trials of empagliflozin, dapagliflozin, canagliflozin, ertugliflozin, and bexagliflozin in adults with type 2 diabetes, chronic kidney disease, or heart failure. Co-primary urinary safety outcomes were any UTI and serious/complicated urinary infection, the latter defined using directly reported serious UTI endpoints or the closest reported severe urinary phenotype. Sensitivity analysis, subgroup analyses by drug and population, leave-one-out analyses, and exploratory meta-regression were performed. A total of 14 studies were included. For the primary any-UTI analysis, 11 studies contributed data, comprising 62,542 participants and 4,685 events. SGLT2 inhibitors were associated with a pooled RR of 1.14 (95

    2026DARU Journal of Pharmaceutical Sciences(2026)
    引用
    AI阅读
    加入学术空间
    2Longitudinal Functional Outcomes Following Rezūm Water Vapor Therapy: A 24-Month Analysis of 1,238 Patients
    Maida Bada,Osama Zaytoun, Ahmed Rabie, Zachary Dovey, Paolo Gontero, Ryan Stevens, Modassar Awan, Mohammad Jaabou,brooke Hildebrand, Luca Sarcinelli,Rocco Papalia, Tommaso Petitti,

    Background Rezūm water vapor therapy has emerged as an effective minimally invasive surgical treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). However, large contemporary studies evaluating the durability of functional outcomes beyond the immediate postoperative period remain limited. Objective To evaluate symptom improvement, urinary function, durability, and predictors of long-term outcomes following Rezūm therapy. Design, Setting, and Participants A retrospective cohort study was conducted among 1,238 consecutive patients who underwent outpatient Rezūm therapy between April 2022 and May 2025 at a high-volume ambulatory surgical center. ( Outcome Measurements and Statistical Analysis Changes in International Prostate Symptom Score (IPSS), quality of life (QoL), peak urinary flow rate (Qmax), post-void residual urine volume (PVR), retreatment-free survival, and patient satisfaction were assessed through 24 months. Longitudinal mixed-effects models, Kaplan-Meier analyses, multivariable regression, receiver operating characteristic analysis, calibration assessment, and decision curve analysis were performed. Results Mean baseline IPSS improved from 23.1 to 8.4 at 24 months (p<0.001). Mean QoL score improved from 4.8 to 1.8 (p<0.001), Qmax increased from 8.7 to 16.0 mL/s (p<0.001), and mean PVR decreased from 146 to 56 mL (p<0.001). Improvements were evident by 3 months and remained stable throughout follow-up (Figure 1). Twenty-four-month retreatment-free survival exceeded 95% (Figure 2). Multivariable analyses demonstrated that elevated baseline PVR and prior urinary retention were associated with less favorable long-term outcomes (Figure 3). Predictive models demonstrated good discrimination and calibration, with area-under-the-curve values approaching 0.80 (Figure 4). Conclusions Rezūm therapy provides durable improvements in urinary symptoms, quality of life, urinary flow, and bladder emptying for up to 24 months. Clinical durability remains high, with low retreatment rates and excellent patient satisfaction. Baseline bladder dysfunction appears to be the principal determinant of long-term outcome. Patient Summary In more than 1,200 men treated with Rezūm therapy, urinary symptoms improved substantially and remained durable for at least two years. Most patients avoided additional procedures and reported high satisfaction. The author is indebted to Gabriella Carroll for her assistance in developing this manuscript. Rezūm therapy produces durable improvements in urinary symptoms through 24 months.

    2026
    引用
    AI阅读
    加入学术空间
    3Rethinking Secondary Cardiovascular Prevention in the Digital Era: Patient Empowerment, Adherence and Optimisation of Guideline-based Care
    Antonio Di Monaco,Simona Giubilato, Domenico D’Amario,Stefania Angela Di Fusco,Maurizio Giuseppe Abrignani,Laura Gatto,Filippo Zilio, Silvia Castelletti, Luigi Pollarolo,Roberta Della Bona,Roberta Rossini,Giovanna Geraci,

    Cardiovascular disease is the leading cause of morbidity and mortality globally. Despite effective treatments, poor adherence limits their long-term benefits. Digital health solutions can enhance clinicians’ ability to optimise guideline-based therapies, improving patient outcomes. Digital tools for remote consultations, monitoring, cardiac device interrogation and clinical decision support systems are now widely available. Digital health monitoring improves care quality, providing value to patients, healthcare professionals, hospitals and governments. This transformation is fostering a future where ‘health’ takes precedence over ‘reactive care’, driven by empowered patients and advanced technologies. Success in this transformation requires not only technology, but also new strategic operational models, optimised workflows and workforce redesign. Health systems that form partnerships with other stakeholders, such as peers, payers, start-ups, life sciences organisations, industries, will be better positioned to improve patient experiences and outcomes. This review examines digital solutions that optimise medical therapy prescriptions, promote patient engagement and address therapeutic inertia in AF, heart failure and coronary artery disease.

    2026European Cardiology Review(2026)
    引用
    AI阅读
    加入学术空间
    4Oscillometry-defined Small Airway Dysfunction As a Predictor of Moderate-to-severe Exacerbations in COPD: a Systematic Review and Meta-Analysis
    Pier-Valerio Mari, Lorenzo Carriera, Simone Ielo, Angelo Coppola,Matteo Siciliano, Veronica Ojetti,Stefano Baglioni,Raffaele Scala,Alberto Ricci

    Small airway dysfunction (SAD) is a pivotal feature of chronic obstructive pulmonary disease (COPD), yet spirometry has limited sensitivity for peripheral airway impairment. Oscillometry offers effort-independent assessment of respiratory mechanics during tidal breathing. We systematically reviewed longitudinal studies reporting the association between baseline oscillometry and subsequent moderate-to-severe acute exacerbations (AE) in COPD. Ratio estimates (OR, HR, IRR) were pooled using a DerSimonian–Laird random-effects model, with sensitivity analyses for effect metric, follow-up, study quality and estimate selection. Six studies (1,317 unique patients; follow-up 1–5 years) met inclusion criteria, and four independent cohorts (n = 1,236) contributed to the meta-analysis. Oscillometry-defined SAD was associated with a higher risk of moderate-to-severe AE (pooled estimate 2.28, 95% CI 1.77–2.94; I² = 0%; 95% prediction interval 1.31–3.98). The association persisted when restricted to hazard and rate ratios (2.23, 95% CI 1.67–2.98) and when the lowest available estimate from each study was pooled (1.60, 95% CI 1.16–2.22). Evidence on discrimination relative to FEV₁ was limited to a single cohort, in which R5–R20 and FEV₁ performed similarly (AUC 0.775 vs. 0.777). Within this small evidence base, oscillometry-defined SAD was associated with exacerbation risk; larger cohorts should define outcome-anchored thresholds and incremental value over spirometry.

    2026
    引用
    AI阅读
    加入学术空间
    5A National Project to Improve the Quality of Secondary Prevention Strategies: the Results of the BRING-UP Prevention Study
    F Colivicchi,M G Abrignani, M Arca, M Averna, A L Catapano,S A Di Fusco, A Di Lenarda, G Fabbri, D Gabrielli, D Lucci,F Oliva, F Orso,

    Recent Italian real-world data show that more than 30% of patients hospitalised for a documented acute atherothrombotic event are readmitted to hospital in the year following discharge. Adherence to guideline recommendations for secondary prevention strategies appears to be largely inadequate. To try to narrow the gap between what is recommended and what is implemented in clinical practice, we designed a national implementation science project, BRING-UP Prevention, based on educational programmes and patient data collection. BRING-UP Prevention is a nationwide, observational, prospective, multicentre study enrolling patients with a documented prior atherothrombotic event. The study consists of two 3-month enrolment phases followed by a 6-month follow-up with end-point evaluation, with each enrolment phase preceded by an educational intervention to discuss guideline recommendations. The first phase was recently completed. These data relate to the primary endpoint, which was the percentage of patients achieving the target of LDL cholesterol <55 mg/dL. The first phase has recently been completed. These data refer to the primary endpoint, which was the percentage of patients achieving the target LDL cholesterol level of <55 mg/dL. 189 cardiology centres collected data on 4790 patients, 2500 discharged from hospital and 2290 managed as outpatients. Follow-up data at 6 months were available for 4643 patients (96.9%). The rate of patients with LDL cholesterol <55 mg/dL increased from 33% to 58.1%, with absolute and relative increases of 25.1 and 76.0%, respectively. Overall, the proportion of patients with LDL cholesterol ≤70 mg/dL increased from 53.5% to 82.2%. At discharge/end of visit, 96% of patients were on statins and 94.7% were still on statins at 6 months. Atorvastatin and rosuvastatin were the most commonly prescribed statins, in more than 75% of cases at high doses. Ezetimibe was prescribed in 84% of cases. The figure shows LDL cholesterol levels at baseline and after 6 months of follow-up. PCSK9Is were prescribed in 7.7% and inclisiran in 2.3% of patients. Pts with partial or total intolerance to statins were 4.5%. Data from the first phase of the BRING-UP Prevention study show that: 1) the rate of pts with a LDL cholesterol increased consistently over the 6-month follow-up period; 2) this result was achieved with high intensity statins, very often in combination with ezetimibe, while the use of new lipid-lowering drugs remained limited. These data show that it is possible to significantly increase the percentage of patients achieving guideline-recommended LDL cholesterol levels with a very favourable cost-benefit approach using a high-intensity statin and ezetimibe. The need to use more potent and costly lipid-lowering approaches is limited to a relatively small proportion of patients.

    2025European Journal of Preventive Cardiology(2025)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 190 篇论文

    合作机构(100)

    罗马大学合作论文 18
    意大利科学领域恢复与治疗研究所合作论文 12
    那不勒斯费德里克二世大学合作论文 11
    罗马第二大学合作论文 9
    博洛尼亚大学合作论文 9
    帕多瓦大学合作论文 8
    佛罗伦萨大学合作论文 8
    Ospedali Riuniti Umberto I合作论文 8
    Fatebenefratelli Hospital,Istituti di Ricovero e Cura a Carattere Scientifico合作论文 6
    米兰大学合作论文 6

    机构统计